Depletion of endogenous gamma interferon (IFN-y) with anti-IFN-y monoclonal antibody resulted in increased numbers of BruceUla abortus in the spleen and liver of infected CBA mice. This increase was accompanied by a decrease in splenomegaly and a lower proportion of macrophages in the spleen. Furthermore, treatment of recipient mice with anti-FN-y antibody blocked the adoptive transfer of resistance with immune T cells. Together, the results indicated that endogenous IFN-y plays an important role in mediating resistance to primary and secondary BruceUla infection.
Resistance to facultative intracellular bacterial pathogens depends on acquired cell-mediated resistance and activation of macrophages by T lymphocytes. Gamma interferon (IFN--y) is believed to be an important mediator of acquired cell-mediated resistance. Injection of recombinant murine IFN--y enhanced resistance of mice to infection with the intracellular bacterial pathogens Brucella abortus (14) , Listeria monocytogenes (9) , and Mycobacterium tuberculosis (8) . In vitro studies have also shown that IFN--y-treated macrophages were better able to inhibit the growth of B. abortus than untreated macrophages (5, 6) , indicating that IFN-y is likely to be an important cytokine in controlling B. abortus infection. However, the role of endogenous IFN--y in host defense against this pathogen is unproven. The availability of neutralizing antibody allows this question to be investigated. Indeed, in vivo administration of anti-IFN-y antibody provides evidence of a requirement for endogenous IFN-y for resolution of L. monocytogenes infection in mice (2, 11) . We report here that neutralization of IFN--y in vivo with a monoclonal antibody (MAb) reduced the in vivo clearance of brucellae from infected CBA/J mice.
To deplete endogenous IFN--y in vivo, each mouse was given a single intraperitoneal injection of 2 mg of rat antimouse IFN--y MAb, partially purified by ammonium sulfate precipitation from ascitic fluid of the R4-6A2 rat-mouse hybridoma (4 (12) . After 14 days of infection, weighed fragments of spleen and liver were homogenized in 5 ml of normal saline with an Ultra Turrax homogenizer (Janke and Kunkel K.G., Breisgau, Germany). The numbers of B. abortus in the organs were established by plating serial 10-fold dilutions of organ homogenates in saline on a horse blood agar plate.
The remaining part of the spleen was used to prepare a spleen cell suspension in phosphate-buffered saline (PBS) with 5% fetal calf serum for determination of cell surface phenotype. Spleen cells from four individual mice were incubated with PBS and the anti-Mac-1 (M1/70) (13) , anti-* Corresponding author.
Thy-1 (30-H12) (10), anti-L3T4a (GK1.5) (3), or anti-Lyt2.2 (53-6.7) (10) MAb and further incubated with fluoresceinconjugated anti-mouse immunoglobulin. Stained cells were analyzed by flow cytometry on a FACScan (Becton Dickinson, Sunnyvale, Calif.).
To test the role of IFN-y in adoptive transfer of T-cellmediated immunity, nylon wool-filtered T cells (7) were prepared from the spleens of normal CBA/J mice and CBA/J mice which had been infected intravenously with 5 x 105 B. abortus strain 19 organisms for 6 to 8 weeks. Naive recipient CBA/J mice, which had been injected intraperitoneally with 2 mg of anti-IFN--y antibody or control proteins 24 h previously, were challenged with 106 B. abortus and then injected with 2 x 107 nylon wool-purified T cells from normal mice or infected mice in sterile PBS (pH 7.4). The numbers of bacteria in spleen and liver were assayed 14 days later, the optimal time for assessing adoptive transfer in Brucella infection (12) . Student's t test was used for all results in this study to assess statistically the differences in mean CFU, spleen size, and percentage of macrophages between groups.
We first tested the effect of the anti-IFN--y MAb on resistance against primary Brucella infection. Mice were injected intraperitoneally with anti-mouse IFN--y MAb or normal rat globulin (2 mg) 24 h before infection with 5 x 105 B. abortus strain 19 organisms, and the numbers of bacterial cells in the spleen and liver of these mice were determined on day 14 of infection ( Fig. 1) . The bacterial counts increased significantly in the spleen and liver of mice that received an injection of the anti-IFN-,y MAb (P < 0.01) compared with controls. The increase in bacterial counts in the liver was greater than in spleen. Multiple injections of anti-IFN--y MAb after infection did not further exacerbate infection compared with that in mice receiving a single injection of the MAb before infection (data not shown).
The above mice treated with the anti-IFN--y MAb showed decreased splenomegaly after infection with B. abortus strain 19 (spleen weight, 340 + 54 mg) (P < 0.01) compared with untreated mice (440 + 47 mg) or control globulintreated mice (439 + 61 mg). This finding was related to the observation by Stevens et al. (14) that injection of recombinant IFN--y increased the spleen size of Brucella-infected mice. We investigated the change in the cell population in the spleens of the MAb-treated mice. Spleen cells were prepared from normal mice, Brucella-infected mice, Brucella-infected mice treated with normal globulin, and infected mice treated with the anti-IFN--y MAb (Fig. 2a) . Anti-IFN--y treatment significantly suppressed this increase in macrophages in infected mice (P < 0.02) compared with untreated infected mice or infected mice treated with normal gammaglobulin (P < 0.03) ( Fig. 2a and b) . These results were confirmed in a repeated experiment (data not presented).
Evidence from an earlier study (2) showed that depletion of IFN--y in listerial infection of mice inhibited the activity of macrophages. The present study showed that depletion of endogenous IFN--y also reduced the numbers of macrophages at the site of infection. For unknown reasons, Thy-1 expression on spleen cells from infected mice was considerably lower than the sum of CD4+ and CD8+ cells, while that of normal spleen cells was equivalent to the sum of CD4+ and CD8+ expression. In the primary response, IFN--y may be produced by either natural killer cells or T lymphocytes (1) , and the anti-IFN-,y MAb could be acting on either of these. Adoptive transfer of resistance, on the other hand, is mediated by T lymphocytes (12) . This system was applied here to study-whether protection conferred by immune T cells is mediated by IFN-,y. Mice were injected intraperitoneally with 2 mg of anti-IFN-y MAb or the same amount of normal rat globulin. Twentyfour hours later, treated mice were given 2 x 107 Brucellaimmune T cells (from 8-week-infected mice) and infected with 106 organisms ofB. abortus strain 19. Controls included mice receiving immune T cells without anti-IFN--y MAb, normal T cells, or saline. They were all infected with the same dose of brucellae. Treatment with anti-IFN--y MAb blocked the protection conferred byBrucella-immune T cells (Fig. 3) . Bacterial counts in the spleen and liver of anti-IFN--y MAb-treated mice were significantly higher than in mice receiving normal rat globulin and immune T cells or untreated mice given immune T cells (P < 0.01).
Overall, this in vivo study indicated that IFN--y produced during the natural host response to B. abortus infection participates in the clearance of bacteria in vivo. This correlated with the results of in vitro studies showing that IFN--y has the ability to inhibit Brucella replication in macrophages NOTES 4901 (5, 6) and in vivo results after injection of recombinant IFN-y (14) . Ironically, IFN--y also appears to mediate the splenomegaly which is a major pathological effect of brucellosis in humans and mice.
